Unlock instant, AI-driven research and patent intelligence for your innovation.

Self-assembling protein nanocage decorated with antibodies (SAPNA) and parts thereof

A protein and antibody technology, applied in peptide/protein components, antibody medical components, immunoglobulin, etc.

Pending Publication Date: 2021-12-14
RGT UNIV OF CALIFORNIA
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So there is huge room for growth and it is likely that most of the big pharma companies have antibody development programs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Self-assembling protein nanocage decorated with antibodies (SAPNA) and parts thereof
  • Self-assembling protein nanocage decorated with antibodies (SAPNA) and parts thereof
  • Self-assembling protein nanocage decorated with antibodies (SAPNA) and parts thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0107] Materials and Methods

[0108] Design of self-assembling protein nanoparticles (SAPNA) modified with antibodies. SAPNA's workflow is an iterative process: design a set of DNA constructs, attempt to express the protein, and if the protein is expressed, characterize the construct and test it for binding to human Fc (hFc). Synthetic DNA fragments were integrated into template scaffolds (cloned into pET22b+ vector) using site-directed mutagenesis and subsequent mutations were performed on any new constructs. The scaffold template (a self-assembling tetrahedral protein cage) originated from work in the Yeates lab at UCLA (1-3). Through a recent collaboration, the unique capabilities of a high-throughput small-angle X-ray scattering (HT-SAXS) beamline developed by our group was used to structurally characterize two scaffold variants in solution under different salt and pH conditions (4 ). These two scaffold variants were used as templates for further functional engineering...

example 2

[0207] Materials and Methods

[0208] Dynamic Light Scattering (DLS) Analysis of SAPNA Binding of Antibodies. Samples were diluted in PBS pH 7.4 and run on a DynaPro Plate Reader III. The DLS acquisition time was 5 seconds, and 5 acquisitions were performed per sample. The temperature is 20 degrees Celsius.

[0209] Primary human T cell expansion assay. Primary human pan-T cells (including CD4 + and CD8 + T cells and some γ / δ T cell subsets) were placed in 96-well plates. On day 1, triplicate wells were treated with soluble SAPNA loaded with different ratios of anti-CD3 / anti-CD28 antibodies or competing technology. Fresh xeno-free medium containing exogenous recombinant human IL-2 was added every 3-4 days. T cells were stained with: live / dead staining, anti-CD3, anti-CD4, anti-CD8, anti-CCR7, anti-CD45RA and anti-CD95 antibodies. T cell differentiation was assessed by flow cytometry using a literature-supported staining protocol for T cell subset identification: T CM ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
affinityaaaaaaaaaa
affinityaaaaaaaaaa
Login to View More

Abstract

The present invention provides for a protein cage polypeptide (or scaffolding protein) useful or capable of forming a hollow tetrahedral pyramid structure, and a "self-assembling protein nanoparticle decorated with antibodies" (SAPNA) which is a chimeric protein assembly comprising: (a) one or more antibodies and (b) the protein cage polypeptide that provides a scaffold upon which to array the antibodies. In some embodiments, the antibody is capable of binding specifically to a pathogenic biological agent, or part thereof.

Description

[0001] Related Patent Applications [0002] This application claims priority to U.S. Provisional Patent Application Serial No. 62 / 838,826, filed April 25, 2019, which is incorporated herein by reference in its entirety. [0003] statement of government support [0004] This invention was made with Government support under Contract No. DE-AC02-05CH11231 awarded by the US Department of Energy. The government has certain rights in this invention. technical field [0005] The present invention is in the field of production of protein-based antibody scaffolds. Background technique [0006] Therapeutic monoclonal antibodies are a huge force in the biopharmaceutical industry, while cancer immunotherapy is a thriving area of ​​intensive research. According to Ecker et al. (5), in 2013, monoclonal antibody products were worth nearly $75 billion, accounting for approximately half of the total sales of all biopharmaceutical products. To put this in perspective, as of the end of 201...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/00A61K39/00C07K14/00C07K16/00C07K19/00
CPCG01N33/6854G01N33/569C07K16/18C07K7/08C07K16/00C07K14/00G01N33/68C07K2319/00
Inventor 柯蒂斯·D·霍奇格雷戈里·L·胡拉托德·O·耶茨
Owner RGT UNIV OF CALIFORNIA